Gyre Therapeutics announced the appointment of Dan Weng, M.D., to its Board of Directors.
Dr. Weng brings nearly four decades of experience in managing global clinical trials across various therapeutic areas.
His strategic insight and extensive regulatory experience will benefit Gyre as they expand their commercial reach and pipeline.
Appointment of Dr. Dan Weng
Dr. Weng joins Gyre Therapeutics' Board of Directors with vast experience in clinical trial management across different therapeutic areas.
Strategic Insight
Dr. Weng's strategic insight will be valuable for Gyre as they continue to grow and advance their pipeline.
Regulatory Expertise
Bringing extensive regulatory experience, Dr. Weng will support Gyre in navigating regulatory requirements.
- The appointment of Dr. Dan Weng strengthens Gyre's leadership with his extensive clinical trial management background.
- Dr. Weng's experience will aid Gyre in expanding its commercial reach and advancing its multi-national pipeline.
The addition of Dr. Dan Weng to Gyre's Board of Directors marks a significant milestone in enhancing the company's expertise and strategic direction.